HRP20050742A2 - 3-methyl-2-(3-(2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis - Google Patents

3-methyl-2-(3-(2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis

Info

Publication number
HRP20050742A2
HRP20050742A2 HR20050742A HRP20050742A HRP20050742A2 HR P20050742 A2 HRP20050742 A2 HR P20050742A2 HR 20050742 A HR20050742 A HR 20050742A HR P20050742 A HRP20050742 A HR P20050742A HR P20050742 A2 HRP20050742 A2 HR P20050742A2
Authority
HR
Croatia
Prior art keywords
treatment
acid derivatives
cyclohexanecarbonyl
ylmethoxy
oxazol
Prior art date
Application number
HR20050742A
Other languages
English (en)
Croatian (hr)
Inventor
Stapper Christian
Gretzke Dirk
Falk Eugen
Goerlitzer Jochen
Keil Stefanie
Schaefer Hans-Ludwig
Glombik Heiner
Wendler Wolfgang
Original Assignee
Sanofi-Aventis Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis Deutschland Gmbh filed Critical Sanofi-Aventis Deutschland Gmbh
Publication of HRP20050742A2 publication Critical patent/HRP20050742A2/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
HR20050742A 2003-02-27 2005-08-26 3-methyl-2-(3-(2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis HRP20050742A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10308355A DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
PCT/EP2004/001578 WO2004076426A1 (de) 2003-02-27 2004-02-19 3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexancarbonyl-amino)-buttersäurederivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose

Publications (1)

Publication Number Publication Date
HRP20050742A2 true HRP20050742A2 (en) 2006-09-30

Family

ID=32920629

Family Applications (3)

Application Number Title Priority Date Filing Date
HR20050743A HRP20050743A2 (en) 2003-02-27 2005-08-26 3-(2-phenyl-oxazol-4-yl methoxy) cyclohexylmethoxy acetic acid derivates and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis
HR20050742A HRP20050742A2 (en) 2003-02-27 2005-08-26 3-methyl-2-(3-(2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis
HR20050744A HRP20050744A2 (en) 2003-02-27 2005-08-26 4-(3-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivates and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HR20050743A HRP20050743A2 (en) 2003-02-27 2005-08-26 3-(2-phenyl-oxazol-4-yl methoxy) cyclohexylmethoxy acetic acid derivates and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
HR20050744A HRP20050744A2 (en) 2003-02-27 2005-08-26 4-(3-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivates and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis

Country Status (34)

Country Link
US (5) US7259177B2 (US07365084-20080429-C00069.png)
EP (3) EP1599455B1 (US07365084-20080429-C00069.png)
JP (3) JP2006519199A (US07365084-20080429-C00069.png)
KR (3) KR20050105492A (US07365084-20080429-C00069.png)
CN (3) CN100398526C (US07365084-20080429-C00069.png)
AR (3) AR043432A1 (US07365084-20080429-C00069.png)
AT (3) ATE435217T1 (US07365084-20080429-C00069.png)
AU (3) AU2004215673B2 (US07365084-20080429-C00069.png)
BR (3) BRPI0407907A (US07365084-20080429-C00069.png)
CA (3) CA2517381A1 (US07365084-20080429-C00069.png)
CL (2) CL2004000391A1 (US07365084-20080429-C00069.png)
CO (2) CO5690578A2 (US07365084-20080429-C00069.png)
DE (4) DE10308355A1 (US07365084-20080429-C00069.png)
DK (3) DK1599452T3 (US07365084-20080429-C00069.png)
EC (2) ECSP055985A (US07365084-20080429-C00069.png)
ES (3) ES2287700T3 (US07365084-20080429-C00069.png)
HR (3) HRP20050743A2 (US07365084-20080429-C00069.png)
IL (2) IL170314A (US07365084-20080429-C00069.png)
MA (3) MA27742A1 (US07365084-20080429-C00069.png)
MX (3) MXPA05008988A (US07365084-20080429-C00069.png)
NO (3) NO20054396L (US07365084-20080429-C00069.png)
OA (2) OA13034A (US07365084-20080429-C00069.png)
PA (1) PA8596801A1 (US07365084-20080429-C00069.png)
PE (3) PE20050292A1 (US07365084-20080429-C00069.png)
PL (3) PL377735A1 (US07365084-20080429-C00069.png)
PT (3) PT1599452E (US07365084-20080429-C00069.png)
RS (1) RS20050594A (US07365084-20080429-C00069.png)
RU (3) RU2005129995A (US07365084-20080429-C00069.png)
SA (1) SA04250153A (US07365084-20080429-C00069.png)
TN (2) TNSN05206A1 (US07365084-20080429-C00069.png)
TW (3) TW200500349A (US07365084-20080429-C00069.png)
UY (2) UY28209A1 (US07365084-20080429-C00069.png)
WO (3) WO2004076426A1 (US07365084-20080429-C00069.png)
ZA (2) ZA200505765B (US07365084-20080429-C00069.png)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576131B2 (en) 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7399777B2 (en) * 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) * 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039532B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039509B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004039533B4 (de) 2004-08-14 2006-09-28 Sanofi-Aventis Deutschland Gmbh Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004060227B3 (de) * 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
AU2006299091A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
US8128969B2 (en) 2006-08-10 2012-03-06 Mimozax Co., Ltd. Hypoglycemic composition containing acacia bark derivative
JP5340287B2 (ja) 2007-08-16 2013-11-13 ソルヴェイ(ソシエテ アノニム) 4−フルオロ置換3−オキソ−アルカン酸のエステル類の調製方法
NZ587261A (en) * 2008-02-29 2012-05-25 Nissan Chemical Ind Ltd Process for producing thiophene compound and intermediate thereof
US7615661B2 (en) * 2008-03-12 2009-11-10 International Flavors & Fragrances Inc. Thioester compounds and their use in fragrance or flavor applications
CN116300352A (zh) 2017-12-13 2023-06-23 佳能株式会社 盒与图像形成装置
CN109810071B (zh) * 2019-03-28 2023-04-21 中国科学院成都生物研究所 一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) * 1990-06-19 1992-09-11 Commissariat Energie Atomique Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
ZA941003B (en) 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 N−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
WO1997026265A1 (en) 1996-01-17 1997-07-24 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
DK0958296T3 (da) 1996-12-31 2003-08-18 Reddys Lab Ltd Dr Heterocykliske forbindelser, fremgangsmåde til deres fremstilling og farmaceutiske præparater, der indeholder dem, og deres anvendelse i behandlingen af diabetes og beslægtede sygdomme
DE19726167B4 (de) * 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
KR20010021936A (ko) 1997-07-16 2001-03-15 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 융합된 1,2,4-티아디아진 유도체, 그의 제조와 사용
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
DE69941777D1 (de) * 1998-03-10 2010-01-21 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
US6664281B1 (en) * 1998-08-27 2003-12-16 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
US6908926B1 (en) * 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
JP2002542245A (ja) 1999-04-16 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 置換イミダゾール、それらの製造および使用
ES2261202T3 (es) * 1999-04-28 2006-11-16 Sanofi-Aventis Deutschland Gmbh Derivados de acido de triarilo como ligandos para el receptor ppar.
YU72201A (sh) 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati di-aril kiseline kao ppar receptorski ligandi
JP2002543200A (ja) 1999-04-30 2002-12-17 ニューロゲン コーポレイション 9H−ピリミド[4、5−b]インドール誘導体:CRF1特異性リガンド
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
CA2376919C (en) 1999-06-18 2008-11-04 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
US6413737B1 (en) 1999-07-09 2002-07-02 Cohesion Technologies, Inc. Ecarin prothrombin protease and methods
WO2001009111A1 (en) 1999-07-29 2001-02-08 Eli Lilly And Company Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists
EP1218341B1 (de) 1999-09-01 2005-08-24 Aventis Pharma Deutschland GmbH Sulfonylcarboxamidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
TWI260321B (en) 1999-09-22 2006-08-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
CZ20021902A3 (cs) 1999-12-03 2002-11-13 Astrazeneca Ab Krystalická forma kyseliny (S)-2-ethoxy-3-[4-(2-{4-methansulfonyloxyfenyl}ethoxy)fenyl]propanové
EP2266665B1 (en) 2000-03-31 2016-05-11 Royalty Pharma Collection Trust Method for the improvement of islet signaling in diabetes mellitus and for its prevention
HUP0300475A3 (en) 2000-04-25 2004-10-28 Kyorin Seiyaku Kk Novel stable crystal of thiazolidinedione derivative and process for producing the same
AU5257401A (en) 2000-04-28 2001-11-12 Asahi Chemical Ind Novel bicyclic compounds
EP1280777B1 (en) 2000-05-11 2005-11-23 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
AU2001264977B2 (en) 2000-05-30 2005-04-14 Merck & Co., Inc. Melanocortin receptor agonists
EE200200634A (et) * 2000-06-09 2004-04-15 Aventis Pharma Deutschland Gmbh Atsüülfenüülkarbamiidi derivaadid, nende saamine ja kasutamine veresuhkrut alandava ravimi valmistamiseks ning neid sisaldav ravim
DE10038709A1 (de) 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (en) * 2000-08-11 2002-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
ES2288982T3 (es) 2000-08-23 2008-02-01 Eli Lilly And Company Derivados de acido oxazolil-ariloxiacetico y su uso como agonistas ppar.
DE60128239T2 (de) * 2000-08-23 2008-01-10 Eli Lilly And Co., Indianapolis Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
WO2002046146A1 (fr) 2000-12-05 2002-06-13 Kyorin Pharmaceutical Co., Ltd. Derives d'acide carboxylique substitues
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
AU2002216097B2 (en) 2000-12-21 2006-09-07 Sanofi-Aventis Deutschland Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
IL156505A0 (en) * 2000-12-25 2004-01-04 Ono Pharmaceutical Co Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient
EP1360172A1 (en) * 2001-02-15 2003-11-12 Pfizer Products Inc. Ppar agonists
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
MXPA03010903A (es) * 2001-06-07 2004-02-17 Lilly Co Eli Moduladores de receptores activados por el proliferador de peroxisomas.
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
WO2003005025A1 (en) 2001-07-03 2003-01-16 Biovitrum Ab Methods for identifying compounds modulating the activity of ppar-gamma
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
BR0212158A (pt) 2001-08-31 2004-07-13 Aventis Pharma Gmbh Derivados de diarilcicloalquila, processos para a sua preparação e sua aplicação como ativadores de ppar
JP2005517008A (ja) 2002-02-05 2005-06-09 イーライ・リリー・アンド・カンパニー Pparモジュレーターとして用いるためのウレアリンカー誘導体
DE10215907A1 (de) 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
JP4579681B2 (ja) 2002-07-09 2010-11-10 ブリストル−マイヤーズ スクイブ カンパニー 抗糖尿病薬および抗肥満薬として有用な置換ヘテロシクロ誘導体および方法
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
EP1599455A1 (de) 2005-11-30
NO20054408D0 (no) 2005-09-22
AU2004215673B2 (en) 2009-10-01
DK1599453T3 (da) 2009-08-24
TNSN05206A1 (en) 2007-06-11
KR20050106461A (ko) 2005-11-09
PE20050292A1 (es) 2005-05-24
US7335671B2 (en) 2008-02-26
CA2517386A1 (en) 2004-09-10
TW200500349A (en) 2005-01-01
US20040209920A1 (en) 2004-10-21
AR043433A1 (es) 2005-07-27
NO20054408L (no) 2005-11-23
PA8596801A1 (es) 2004-09-16
CN1753879A (zh) 2006-03-29
TW200510352A (en) 2005-03-16
MA27736A1 (fr) 2006-02-01
ATE435217T1 (de) 2009-07-15
DK1599452T3 (da) 2007-10-01
AU2004215672A1 (en) 2004-09-10
RU2005129992A (ru) 2006-02-10
AR043427A1 (es) 2005-07-27
CL2004000391A1 (es) 2005-01-07
HRP20050743A2 (en) 2006-08-31
IL170316A (en) 2010-11-30
DE10308355A1 (de) 2004-12-23
US7259177B2 (en) 2007-08-21
UY28210A1 (es) 2004-09-30
MA27737A1 (fr) 2006-02-01
ES2329366T3 (es) 2009-11-25
ATE430738T1 (de) 2009-05-15
ES2287700T3 (es) 2007-12-16
CN1753881A (zh) 2006-03-29
AU2004215673A1 (en) 2004-09-10
MA27742A1 (fr) 2006-02-01
ECSP055986A (es) 2006-01-16
PE20040959A1 (es) 2005-01-17
PT1599453E (pt) 2009-07-14
PT1599455E (pt) 2009-09-29
ZA200505765B (en) 2006-05-31
US20050101637A1 (en) 2005-05-12
NO20054398D0 (no) 2005-09-22
CO5690580A2 (es) 2006-10-31
CA2517381A1 (en) 2004-09-10
BRPI0407758A (pt) 2006-02-14
JP2006519194A (ja) 2006-08-24
AU2004215677B2 (en) 2010-01-07
TNSN05204A1 (en) 2007-06-11
DE502004009690D1 (de) 2009-08-13
JP2006519199A (ja) 2006-08-24
AR043432A1 (es) 2005-07-27
US20050215596A1 (en) 2005-09-29
MXPA05008995A (es) 2005-10-18
CN100398526C (zh) 2008-07-02
WO2004076428A1 (de) 2004-09-10
DE502004004139D1 (de) 2007-08-02
OA13035A (en) 2006-11-10
KR20050105492A (ko) 2005-11-04
RS20050594A (en) 2007-12-31
PE20050293A1 (es) 2005-05-24
PL378437A1 (pl) 2006-04-03
ES2326418T3 (es) 2009-10-09
CN100439347C (zh) 2008-12-03
BRPI0407907A (pt) 2006-02-14
KR20050106462A (ko) 2005-11-09
CN1756748A (zh) 2006-04-05
DK1599455T3 (da) 2009-11-09
PL377735A1 (pl) 2006-02-20
PL378130A1 (pl) 2006-03-06
EP1599452B1 (de) 2007-06-20
AU2004215672B2 (en) 2010-01-07
DE502004009453D1 (de) 2009-06-18
AU2004215677A1 (en) 2004-09-10
US7365084B2 (en) 2008-04-29
NO20054396D0 (no) 2005-09-22
ZA200505768B (en) 2005-11-23
PT1599452E (pt) 2007-09-12
CA2516620A1 (en) 2004-09-10
MXPA05008951A (es) 2005-11-04
ECSP055985A (es) 2006-01-16
WO2004076426A1 (de) 2004-09-10
TW200508210A (en) 2005-03-01
CO5690578A2 (es) 2006-10-31
UY28209A1 (es) 2004-09-30
SA04250153A (ar) 2005-12-03
CN100439345C (zh) 2008-12-03
EP1599455B1 (de) 2009-07-01
JP2006519193A (ja) 2006-08-24
OA13034A (en) 2006-11-10
RU2005130002A (ru) 2006-01-27
US20080167354A1 (en) 2008-07-10
EP1599453B1 (de) 2009-05-06
US20080015238A1 (en) 2008-01-17
NO20054396L (no) 2005-11-11
RU2005129995A (ru) 2006-01-27
EP1599453A1 (de) 2005-11-30
ATE365159T1 (de) 2007-07-15
EP1599452A1 (de) 2005-11-30
HRP20050744A2 (en) 2006-09-30
IL170314A (en) 2010-11-30
WO2004076427A1 (de) 2004-09-10
MXPA05008988A (es) 2005-10-18
NO20054398L (no) 2005-11-02
US7872034B2 (en) 2011-01-18
CL2004000392A1 (es) 2005-04-22
BRPI0407814A (pt) 2006-02-14

Similar Documents

Publication Publication Date Title
HRP20050742A2 (en) 3-methyl-2-(3-(2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis
HRP20050740A2 (en) Diarylcycloalkyl derivatives, method for their production and their use as medicaments
EP1784388B8 (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
YU45403A (sh) Novi 1,2-difenil-azetidinoni, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena za lečenje poremećaja u metabolizmu lipida
SE0301010D0 (sv) Novel compounds
ATE534650T1 (de) Neue cyanothiazolide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
SE0301009D0 (sv) Novel compounds
BR0212158A (pt) Derivados de diarilcicloalquila, processos para a sua preparação e sua aplicação como ativadores de ppar
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
NO20063761L (no) Sulfonamidderivater for behandling av sykdommer
IL176914A0 (en) Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, method for the production thereof and their use as medicaments
SG151336A1 (en) 1,3,4-oxadiazol-2-ones as ppar delta
IL178167A0 (en) 1,3,4-oxadiazol-2-ones as ppar delta modulators
IL176915A0 (en) Cycloalkyl substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, method for the production thereof and their use as medicaments
HRP20050715A2 (en) Substituted 3-(benzoylureido)-thiophene derivatives, method for the production and use thereof
HRP20050741A2 (en) 1,3-substituted cycloalkyl containing acidic, mainly heterocyclic groups, corresponding production method and use of said derivatives as medicaments
HRP20050737A2 (en) Arylcycloalkyl derivatives with branched side chains as ppar receptor modulators, method for their production and their use as medicaments
HRP20050739A2 (en) Cycloalkyl-substituted alkanoic acid derivatives, methods for the production thereof, and use thereof as a medicament
CO5690587A2 (es) Derivados de acido bensoilureidopiridil-piperidin-y pirrolidin carboxilico sustituido, metodo para su produccion y su uso
TNSN06233A1 (en) 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments
HRP20050738A2 (en) Cycloalkyl derivatives comprising bioisosteric carboxylic acid groups, method for the production thereof, and use thereof as a medicament
SG153698A1 (en) Composition and method for prevention and treatment of alzheimeræs disease
MX2007010841A (es) 8-pirrolidinobenzimidazoles biciclicos sustituidos, un metodo para su produccion y su uso como medicamentos.
MXPA05007515A (es) Metodo para la produccion de derivados de acil-fenil-urea sustituidos por amino-carbonilo y el uso de los mismos.
EA200600318A1 (ru) ПРОИЗВОДНЫЕ 3-НИТРОПИРАЗОЛО[1,5-a]ПИРИМИДИНОВ, СПОСОБ ИХ ПОЛУЧЕНИЯ, ЛЕКАРСТВЕННОЕ СРЕДСТВО (ВАРИАНТЫ) И СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С МОДУЛЯЦИЕЙ РЕЦЕПТОРА ГАМК(ВАРИАНТЫ)

Legal Events

Date Code Title Description
ODRP Renewal fee for the maintenance of a patent

Payment date: 20051229

Year of fee payment: 3

A1OB Publication of a patent application
OBST Application withdrawn